 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| alogabat (RG7816) / Roche
Trial completion: A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD) (clinicaltrials.gov) - Jun 14, 2024
P2, N=103, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed
- || alogabat (RG7816) / Roche
Trial completion date, Trial primary completion date: Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype. (clinicaltrials.gov) - Jun 3, 2024
P2, N=56, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Trial completion date: Mar 2025 --> Sep 2025 | Trial primary completion date: Mar 2025 --> Sep 2025
- || alogabat (RG7816) / Roche
Enrollment closed: A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD) (clinicaltrials.gov) - Mar 3, 2024
P2, N=103, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Mar 2025 --> Sep 2025 | Trial primary completion date: Mar 2025 --> Sep 2025 Recruiting --> Active, not recruiting
- || alogabat (RG7816) / Roche
Trial completion date, Trial primary completion date: A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD) (clinicaltrials.gov) - Jan 5, 2024
P2, N=105, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial completion date: Dec 2023 --> May 2024 | Trial primary completion date: Dec 2023 --> May 2024
- | alogabat (RG7816) / Roche
Phase classification: Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype. (clinicaltrials.gov) - Nov 13, 2023
P2, N=56, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Dec 2023 --> May 2024 | Trial primary completion date: Dec 2023 --> May 2024 Phase classification: P2a --> P2
- || alogabat (RG7816) / Roche
Trial initiation date: Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype. (clinicaltrials.gov) - Jun 26, 2023
P2a, N=56, Recruiting, Sponsor: Hoffmann-La Roche
Phase classification: P2a --> P2 Initiation date: Mar 2025 --> Jul 2023
- ||| alogabat (RG7816) / Roche
Enrollment open, Trial initiation date: Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype. (clinicaltrials.gov) - Jun 13, 2023
P2a, N=56, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Mar 2025 --> Jul 2023 Not yet recruiting --> Recruiting | Initiation date: Jun 2023 --> Mar 2025
- || alogabat (RG7816) / Roche
Trial initiation date: Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype. (clinicaltrials.gov) - Jan 18, 2023
P2a, N=56, Not yet recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting | Initiation date: Jun 2023 --> Mar 2025 Initiation date: Jan 2023 --> Jun 2023
- |||| alogabat (RG7816) / Roche
New P2a trial: Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype. (clinicaltrials.gov) - Nov 29, 2022
P2a, N=56, Not yet recruiting, Sponsor: Hoffmann-La Roche
- ||| alogabat (RG7816) / Roche
Enrollment change: A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD) (clinicaltrials.gov) - Apr 22, 2021
P2, N=105, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Jan 2023 --> Jun 2023 N=210 --> 105
- |||| alogabat (RG7816) / Roche
Enrollment open: A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD) (clinicaltrials.gov) - Feb 23, 2021
P2, N=210, Recruiting, Sponsor: Hoffmann-La Roche
N=210 --> 105 Not yet recruiting --> Recruiting
- ||| alogabat (RG7816) / Roche
Trial initiation date: A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD) (clinicaltrials.gov) - Dec 22, 2020
P2, N=210, Not yet recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Initiation date: Nov 2020 --> Mar 2021
- ||| alogabat (RG7816) / Roche
Trial completion date, Trial initiation date, Trial primary completion date: A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD) (clinicaltrials.gov) - Jun 11, 2020
P2, N=210, Not yet recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Nov 2020 --> Mar 2021 Trial completion date: Dec 2023 --> Sep 2023 | Initiation date: Jun 2020 --> Oct 2020 | Trial primary completion date: Dec 2023 --> Sep 2023
- ||||| alogabat (RG7816) / Roche
New P2 trial: A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD) (clinicaltrials.gov) - Mar 6, 2020
P2, N=210, Not yet recruiting, Sponsor: Hoffmann-La Roche
- || alogabat (RG7816) / Roche
Trial completion: A 2 Part Study to Assess the Relative Bioavailability of Tablet Formulation Compared to Capsule Formulation and the Effect of Food and Taste Assessment on the Tablet Formulation in Healthy Participants (clinicaltrials.gov) - Jun 26, 2019
P2, N=24, Completed, Sponsor: Hoffmann-La Roche
Trial completion date: Dec 2023 --> Sep 2023 | Initiation date: Jun 2020 --> Oct 2020 | Trial primary completion date: Dec 2023 --> Sep 2023 Active, not recruiting --> Completed
- | alogabat (RG7816) / Roche
Enrollment closed: A 2 Part Study to Assess the Relative Bioavailability of Tablet Formulation Compared to Capsule Formulation and the Effect of Food and Taste Assessment on the Tablet Formulation in Healthy Participants (clinicaltrials.gov) - Apr 4, 2019
P2, N=24, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || alogabat (RG7816) / Roche
Enrollment open: A 2 Part Study to Assess the Relative Bioavailability of Tablet Formulation Compared to Capsule Formulation and the Effect of Food and Taste Assessment on the Tablet Formulation in Healthy Participants (clinicaltrials.gov) - Mar 20, 2019
P2, N=24, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || alogabat (RG7816) / Roche
New P2 trial: A 2 Part Study to Assess the Relative Bioavailability of Tablet Formulation Compared to Capsule Formulation and the Effect of Food and Taste Assessment on the Tablet Formulation in Healthy Participants (clinicaltrials.gov) - Feb 20, 2019
P2, N=24, Not yet recruiting, Sponsor: Hoffmann-La Roche
- || alogabat (RG7816) / Roche
Trial completion, Enrollment change: A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RO7017773 in Healthy Participants (clinicaltrials.gov) - Jan 22, 2019
P1, N=4, Completed, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Completed | N=18 --> 4
- || alogabat (RG7816) / Roche
Enrollment open: A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RO7017773 in Healthy Participants (clinicaltrials.gov) - Dec 26, 2018
P1, N=18, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed | N=18 --> 4 Not yet recruiting --> Recruiting
- || alogabat (RG7816) / Roche
New P1 trial: A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RO7017773 in Healthy Participants (clinicaltrials.gov) - Dec 13, 2018
P1, N=18, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | alogabat (RG7816) / Roche
Trial completion, Trial completion date, Trial primary completion date: Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513 (clinicaltrials.gov) - Oct 10, 2018
P1, N=15, Completed, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial completion date: Nov 2018 --> Jun 2018 | Trial primary completion date: Nov 2018 --> Jun 2018
- | alogabat (RG7816) / Roche
New P1 trial: Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513 (clinicaltrials.gov) - Apr 24, 2018
P1, N=15, Not yet recruiting, Sponsor: Hoffmann-La Roche